For patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the ...

Discover how inebilizumab reduces flares and improves remission rates in IgG4-related disease in this phase 3 clinical trial.

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.